A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol).
Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors:
* Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer)
* ECOG score at baseline (0 vs 1)
* Geographic region (Asia vs ROW)

开始日期2026-12-01

申办/合作机构

Evergreen Therapeutics, Inc

NCT05106127

/ Not yet recruiting临床2期

A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients.
A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

开始日期2026-08-01

申办/合作机构

Evergreen Therapeutics, Inc

NCT07275216

/ Not yet recruiting临床2期IIT

Phase 2 Study of Pembrolizumab With Chemotherapy in Frail Patients With Newly Diagnosed Classical Hodgkin Lymphoma

This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma who aren't candidates for standard anthracycline-based treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Dacarbazine is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells and slow down or stop cancer growth. Pembrolizumab in combination chemotherapy may be a safe and effective alternative treatment option for frail patients with Hodgkin lymphoma who can't receive standard anthracycline-based treatment.

开始日期2026-07-01

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与帕博利珠单抗相关的临床结果

登录后查看更多信息

100 项与帕博利珠单抗相关的转化医学

登录后查看更多信息

100 项与帕博利珠单抗相关的专利（医药）

登录后查看更多信息

9,352

项与帕博利珠单抗相关的文献（医药）

2026-12-31·Human Vaccines & Immunotherapeutics

Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities

Review

作者: Zang, Qiwei ; Jia, Huijun ; Wei, Hongyu ; Gong, Yifan ; Zhao, Chengguang

Immunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.

2026-12-31·ANNALS OF MEDICINE

Application of artificial intelligence in head and neck squamous cell carcinoma

Review

作者: Tian, Jiaxin ; Wang, Peipei ; Zheng, Guowan ; Chen, Yunzhao ; Ren, Xinxin

Background: Head and neck squamous cell carcinoma (HNSCC) emerges from the mucosal linings of the paranasal sinuses, nasal cavities, oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. Despite significant advances in understanding its epidemiology, pathogenesis and treatment strategies, the survival rate of HNSCC has shown little improvement over the last 40 years, maintaining a 5-year survival outcome of approximately 50%. Although the emergence of immunotherapies, such as pembrolizumab-FDA-approved for first-line HNSCC treatment-has shown promise in enhancing therapeutic outcomes and patient prognosis, merely a limited portion of individuals with HNSCC experience advantages from these therapeutic approaches.Main body: Consequently, the need for novel biomarkers to refine treatment selection is increasingly urgent. The swift progress of artificial intelligence (AI) in medicine has enabled large-scale biomarker screening and the creation of predictive models, which are critical for identifying immunotherapy responders and predicting patient outcomes. This review summarizes current immunotherapeutic approaches in HNSCC and examines the role of AI in advancing immunotherapy strategies.Discussion: Furthermore, it discusses the challenges, opportunities and strategies associated with integrating AI into clinical practice. Finally, the review highlights the transformative potential of AI in HNSCC immunotherapy and offers perspectives on its future applications.

2026-12-31·PLATELETS

Immune thrombocytopenia triggered by dostarlimab in a patient with endometrial carcinoma: first reported case

Article

作者: Pazmiño-Zambrano, M. Belén ; García-Jaén, Pablo ; González-Porras, José Ramón ; Bastida, José María ; Fernández-Sánchez, Adolfo ; Reguera-Puertas, Pablo ; Puerta-Vázquez, Carlos

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for various malignancies, but they are associated with a range of immunerelated adverse events, including rare hematological complications. Immune thrombocytopenia (ITP) has been reported with other antiPD1 agents such as nivolumab and pembrolizumab, but to date, no cases have been described with dostarlimab. We report the first case of ITP in a patient receiving dostarlimab for relapsed endometrial carcinoma. A 55yearold woman developed severe thrombocytopenia (3 × 10⁹/L) accompanied by rectal bleeding, resulting in a lifethreatening condition. Secondary causes were excluded, and bone marrow findings supported a diagnosis of ITP. Initial treatment with highdose corticosteroids and intravenous immunoglobulin achieved only a partial response, while sustained platelet recovery was obtained with the addition of romiplostim. The patient remained on dostarlimab following hematological recovery without further episodes of ITP. This case highlights a potentially lifethreatening adverse effect of a widely used immunotherapy and underscores the importance of early recognition and timely escalation of treatment in ICIinduced ITP.

11,632

项与帕博利珠单抗相关的新闻（医药）

1小时内

·PRNewswire

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

Feb. 24, 2026 -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", SEHK: 1877.HK; SSE: 688180). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene's ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences' JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types. This collaboration builds on the encouraging Phase I proof-of-concept clinical data generated with ATG-037. At a time when resistance to checkpoint inhibitors (CPIs) has become a major clinical challenge, the Phase I study evaluating ATG-037 in combination with CPIs has already demonstrated promising potency into reversing CPI resistance. Beyond validating the synergistic potential of these two innovative drugs, this collaboration aims to advance the efficacy of existing immunotherapies and extend the overall survival (OS) of cancer patients through a "triple-axis" approach that incorporates immune checkpoint signalling, anti-angiogenesis, and the alleviation of adenosine-mediated immunosuppression. ATG-037, Antengene's orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies. In preclinical studies, ATG-037 demonstrated stronger inhibition of cell-surface CD73 enzymatic activity and overcame the "hook effect" commonly observed with antibody-based approaches. In addition, ATG-037's higher tissue penetration compared with antibodies may facilitate complete CD73 inhibition at the cellular level. ATG-037 has demonstrated encouraging clinical activity in combination with anti–PD-1 therapy in patients with CPI-resistant melanoma and non-small cell lung cancer (NSCLC), based on the latest data presented at Antengene's R&D Day in November 2025. In the ongoing Phase I/Ib STAMINA-01 study, the combination achieved an objective response rate (ORR) of 33.3% with a disease control rate (DCR) of 100% in patients with CPI-resistant melanoma, and an ORR of 21.4% with a DCR of 71.4% in patients with CPI-resistant NSCLC. The dataset was generated in Australia in patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti–PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti–PD-1 and anti–CTLA-4 (ipilimumab). These results support ATG-037's clinically meaningful activity across multiple tumor types, particularly in patients with prior immunotherapy resistance. Importantly, ATG-037 has demonstrated a favorable safety and tolerability profile in combination treatment, with no new or unexpected safety signals observed, including in patients receiving long-term therapy.Grade 3 or higher treatment-related adverse events only occurred in 7.9% of patients. Responses have also shown encouraging durability, including a patient who achieved a complete response and has remained on study for over three years and is currently receiving ATG-037 monotherapy for more than a year, as well as multiple patients with durations of response exceeding 12 months. These data support ATG-037's potential role as a backbone agent for next-generation immuno-oncology combination regimens. JS207, Junshi Biosciences' independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. JS207's preclinical studies demonstrated its robust anti-tumor efficacy in multiple tumor models and supported a differentiated mechanism of action, with VEGFA shown to enhance JS207's antigen binding activity, T-cell activation potency and internalization of cell-surface PD-1. In a poster presented at ESMO Asia 2025, JS207 monotherapy showed encouraging efficacy across solid tumors. 62 patients with PD-L1 positive NSCLC received JS207 monotherapy as first-line treatment, and achieved an ORR of 58.1% and a DCR of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing phase II clinical studies, exploring its use in combination with chemotherapy, monoclonal antibodies, antibody-drug conjugates (ADCs) and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types, with nearly 500 patients enrolled. Based on the accumulated data from these studies, the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application, allowing Junshi Biosciences to initiate an open-label, two-arm, randomized, active-controlled, Phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative NSCLC. The scientific rationale for the collaboration is based on the complementary and potentially synergistic mechanisms of CD73 inhibition and dual PD-1/VEGF targeting. CD73 is recognized as a key regulator of immune suppression and angiogenesis within the tumor microenvironment through the generation of adenosine, which can dampen anti-tumor immune responses. In both clinical and preclinical settings, CD73 inhibitors have demonstrated meaningful synergy with anti–PD-1 monoclonal antibodies. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed approaches has the potential to enhance and sustain therapeutic effects. Together, the combination of ATG-037 with JS207 represents a potential "triple-axis" approach that simultaneously modulates immune checkpoint signaling, angiogenesis, and the adenosine pathway. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved OS. We look forward to working closely with Junshi Biosciences and leveraging our respective expertise in target biology and clinical development to accelerate the evaluation of ATG-037 in combination with JS207 across multiple solid tumor types, with the goal of identifying clinical signals and delivering more innovative treatment options for patients in Mainland China. Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies indications. To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore). The content above comes from the network. if any infringement, please contact us to modify.

临床结果免疫疗法临床申请

1 小时之前

·摩熵医药

仅1月！9亿重磅品种国内被拒/撤回？

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 2月24日，一则来自中国国家药品监督管理局（NMPA）的通知件送达消息，让业界的目光再次聚焦到卫材的“王牌”--甲磺酸仑伐替尼胶囊（商品名：乐卫玛/Lenvima）身上。这款年销近10亿的重磅肝癌药，在2026年1月22日提交的两项补充申请，赫然出现在了“药品通知件”的名单中。这，通常意味着申请“不予批准”或被申请人主动“撤回”。截图来源：NMPA官网 01 “乐卫玛”失速：从年销18亿到补充申请被拒甲磺酸仑伐替尼胶囊作为一款由日本卫材研发的多靶点酪氨酸激酶抑制剂，自2018年登陆中国以来，一直是肝癌治疗领域的基石药物。从最初的不可切除肝细胞癌，到后来的甲状腺癌，它构建了庞大的市场版图。摩熵医药的数据显示，这款药物在国内市场一度势如破竹，2022年院内销售额突破18亿元大关。即便在竞争加剧的2024年，其全终端院内销售额仍超11亿元，并在2025年前三季度保持了14.10%的同比增长，销售额超过9亿元。截图来源：全终端医院销售数据库（查数据.找摩熵）从企业竞争格局来看，2025年前三季度，卫材以近50%的市场份额，稳坐该品种的院内头把交椅。然而，数据的增长未能掩盖潜在的风暴。2026年1月22日，卫材为其提交的补充申请（受理号：JYHB2600054/53）获得CDE受理。仅仅一个月，收到NMPA的通知件，剧情急转直下。这不禁让人猜测，究竟是何种原因，让这款明星药物在关键时刻踩下了刹车？截图来源：全终端医院销售数据库（查数据.找摩熵） 02 连环失利：K药组合疗法的“三期魔咒” 2025年，卫材的甲磺酸仑伐替尼胶囊与默沙东的帕博利珠单抗（俗称“K药”）的两项关键III期临床研究均未达到主要终点，遭遇双重挫败。 lLEAP-012研究：旨在评估“K药+仑伐替尼+TACE（肝动脉化疗栓塞术）”三联疗法治疗不可切除的非转移性肝细胞癌。然而，预设的期中分析给出了残酷的答案：相比于单独使用TACE，三联疗法的首要目标——延长患者总生存期（OS）——未达到统计学意义。 lLEAP-015研究：聚焦于HER2阴性胃癌或胃食管交界处腺癌的一线治疗。该研究的最终分析结果同样令人失望：“K药+仑伐替尼+化疗”的组合，在与单纯化疗的头对头比较中，总生存期（OS）这一主要终点再次折戟。尽管此前期中分析的无进展生存期（PFS）有所改善，但无法挽回OS失利的败局。在肿瘤药研发中，III期临床的成败，直接决定了新药或新适应症的生死。这两场关键战役的失利，无疑给仑伐替尼的未来蒙上了一层厚厚的阴影。补充申请的被拒，很可能正是源于监管部门对这些最新、且不利的临床数据的审慎考量。 03 群狼环伺：仿制药大军压境，原研地位动摇？甲磺酸仑伐替尼胶囊的仿制药竞争已进入白热化阶段。目前国内已有18家企业手握生产批文，其中17家已过评，涉及重庆药友、成都倍特、湖南科伦、齐鲁制药、正大天晴……这些本土巨头构筑起的仿制药护城河，正在不断挤压原研药的利润空间。截图来源：过评药品汇总数据库（查数据.找摩熵）从仿制药布局来看，目前仅山东鲁抗医药一家药企以仿制4类报产，也已进入审评流程，预示着未来价格战将更加惨烈。截图来源：中国药品审评数据库（查数据.找摩熵）在这样的背景下，任何关于安全性和有效性的负面信号，都会被无限放大。卫材原本寄希望于通过补充申请巩固或拓展市场，但在核心联合疗法的III期临床双双失利后，监管的绿灯也随之熄灭。结语从年销18亿的巅峰到补充申请被拒的低谷，甲磺酸仑伐替尼胶囊的命运转折令人唏嘘。这不仅是一个品种的挫折，更是整个免疫肿瘤（IO）+酪氨酸激酶抑制剂（TKI）联合疗法热潮中，一次深刻的降温。它警示着行业：在资本的狂热追逐之外，唯有坚实可靠的临床数据，才是创新药长青的唯一基石。对于卫材而言，如何重新评估“乐卫玛”的产品生命周期，并制定应对策略，将是其2026年必须直面的严峻课题。而对于国内患者和医保基金来说，这或许意味着，在不久的未来，他们将有更多、也更经济的优质选择。 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 2024年中国1类新药靶点白皮书-202503 中国AI医疗健康企业创新发展百强榜单-202502 2024年FDA批准上市的新药分析报告-202501 小分子化药白皮书（上）-202501 2024年中国医疗健康投融资全景洞察报告-202501 2024年医保谈判及市场分析报告-202501 近期更多摩熵咨询热门报告识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请摩熵医药企业版免费试用！

临床3期申请上市临床成功

4 小时之前

·ioncology

HER2研究者说胃癌篇丨刘天舒教授：改写临床实践，德曲妥珠单抗成为中国首个且唯一的胃癌二线抗HER2靶向治疗策略

点击蓝字，关注我们编者按：胃癌是我国年新发病例位居第4位的恶性肿瘤，其中HER2阳性胃癌患者占11.47%，预后较差，为国民健康带来了严峻负担。纵观HER2阳性胃癌的治疗格局，晚期患者一线治疗、三线治疗均可从抗HER2精准治疗中取得获益，但截至2025年，二线治疗仍以化疗联合抗血管生成治疗为主，欠缺抗HER2治疗手段，疗效及安全性均有待提升。2026年1月14日，基于DESTINY-Gastric04研究，中国国家药品监督管理局（NMPA）正式批准新型靶向HER2的抗体偶联药物（ADC）德曲妥珠单抗（T-DXd）二线治疗HER2阳性胃癌适应症，“单药适用于既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者”，填补了国内空白，满足了患者多方面的治疗需求。DESTINY-Gastric04研究PI、复旦大学附属中山医院刘天舒教授特别于“HER2研究者说胃癌篇”栏目撰文，深度解析DESTINY-Gastric04研究与中国患者临床需求匹配度，展望未来HER2阳性胃癌治疗格局发展，为临床实践指引方向。专家寄语 2010年，ToGA研究首次在胃癌领域证实了抗HER2治疗有效延长生存的作用。但是，抗HER2治疗这条路并不容易。历经十余年的探索，所有关于HER2阳性胃癌的二线治疗均以失败而告终。2021年，新型ADC T-DXd的DESTINY-Gastric02研究在欧美首次证实了HER2阳性胃癌二线抗HER2治疗获益，中位总生存期（OS）首度突破12个月，为临床带来了新的希望。2026年1月14日，基于DESTINY-Gastric04研究的无进展生存期（PFS）和OS双阳性结果，T-DXd正式获得NMPA批准，单药适用于既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。在DESTINY-Gastric04研究中，T-DXd成功挑战当前标准的雷莫西尤单抗联合紫杉醇（RAM+PTX）二线治疗方案，为临床带来了更优秀的治疗选择，可有效满足患者更长生存时间、更好生活质量的治疗需求，展现了胃癌二线抗HER2治疗的广阔前景。自此，中国迎来了首个且唯一的胃癌二线抗HER2治疗方案，填补了抗HER2治疗空白，将改写指南与临床实践。相信在不久后，我们将看到T-DXd被写入中国的相关指南。纵览HER2阳性胃癌治疗格局把握未满足临床需求胃癌是我国常见的消化系统肿瘤，年新发35.87万例，死亡26.04万例，分别位居中国恶性肿瘤的第4位和第3位，约占全球的一半[1]。其中，我国11.47%的胃癌患者中存在HER2扩增或过表达，预后较差，为我国国民健康带来了严重负担[2]。随着抗HER2治疗的发展，HER2阳性胃癌也迎来了相应的精准治疗策略。在一线治疗方面，对于HER2高表达且PD-L1 CPS≥1分的人群，基于KEYNOTE-811研究[3]，帕博利珠单抗联合曲妥珠单抗与化疗为标准治疗方案，mPFS达到10个月，mOS为20.0个月；对于HER2高表达且PD-L1 CPS＜1分的人群，则仍基于ToGA研究，应用曲妥珠单抗联合化疗方案[4]。在二线治疗方面，抗HER2治疗历经十余年探索，截至2025年在我国仍属空白，缺乏有效的抗HER2治疗手段。Tytan研究的酪氨酸激酶抑制剂（TKI）拉帕替尼[5]、GATSBY研究的ADC恩美曲妥珠单抗（T-DM1）[6]、T-ACT研究的曲妥珠单抗[7]等相关抗HER2研究均以失败告终，mOS不超过11个月。目前，我国HER2阳性胃癌仍以RAM+PTX为标准治疗方案，RAINBOW研究显示mOS仅为9.6个月[8]。在三线及其后治疗方面，基于DESTINY-Gastric01研究[9]、DESTINY-Gastric06研究[10]、RC48-C008研究[11]，抗HER2 ADC已成为标准治疗选择。其中，T-DXd是当前首个且唯一在三线治疗中使mOS突破1年的ADC，改善了患者预后。纵览HER2阳性胃癌的治疗格局，其二线抗HER2治疗仍属空白，难以满足患者精准治疗的需求。在抗HER2治疗三线能取得超过1年的mOS前提下，当前二线标准的RAM+PTX方案mOS仅9.6个月，其他探索也未能超过11个月，患者OS仍有较大提升空间。此外，现有标准治疗手段多会联合化疗，相关不良反应令患者闻之色变，对患者的生活质量及治疗依从性均有一定影响。因此，补全抗HER2治疗版图，为HER2阳性胃癌患者二线治疗寻求更优的治疗策略是临床的迫切需求。 DG04研究实现二线抗HER2突破契合中国患者治疗需求面对HER2阳性胃癌的二线治疗瓶颈，2021年，新型ADC T-DXd的DESTINY-Gastric02研究[12]在欧美人群首次证实了其对HER2阳性晚期胃癌的二线治疗获益，mOS突破12个月。在此基础上，III期DESTINY-Gastric04研究[13]再获成功，T-DXd单药二线治疗成功挑战了当前的标准RAM+PTX方案。基于该研究，2026年1月14日，NMPA正式批准T-DXd单药适用于既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。自此，我国终于迎来了当前首个且唯一的胃癌二线抗HER2治疗方案，填补了治疗空白，将改写诊疗指南与临床实践。 DESTINY-Gastric04研究是一项国际多中心、随机、对照 III期临床研究，其中国部分由北京大学肿瘤医院沈琳教授领衔，我单位非常荣幸参与其中。该研究了共纳入了494例曲妥珠单抗联合化疗经治的HER2阳性（IHC 3+或IHC 2+/ISH+）局部晚期或转移性胃癌/胃食管结合部癌患者，分别予以T-DXd或RAM+PTX二线治疗。结果显示，T-DXd单药较RAM+PTX显著延长mOS，为14.7个月vs 11.4个月（HR=0.70，95%CI：0.55-0.90，P=0.0044），2年OS率翻倍，为29.0% vs 13.9%。这是HER2阳性胃癌二线治疗领域OS首次突破1年，为当前最长OS数值，可有效满足患者更长生存的临床需求。 DESTINY-Gastric04研究OS结果 T-DXd可有效控制疾病进展，为患者带来治疗疗效的直观体验。DESTINY-Gastric04研究显示，T-DXd单药较RAM+PTX显著延长mPFS，为6.7个月 vs 5.6个月（HR=0.73，95%CI：0.59-0.92，P=0.0074），延缓了疾病进展。尤为值得注意是，该研究纳入了约20%的中国大陆人群，对于我国患者，T-DXd的mPFS更加突出，两组分别为7.2个月 vs 5.6个月，疾病进展或死亡风险降低38% (HR=0.62, 95% CI: 0.38-1.00)，提示T-DXd单药为中国HER2阳性胃癌患者二线治疗带来了更好的预后。 DESTINY-Gastric04研究中国人群PFS 在安全性方面，T-DXd较当前标准二线RAM+PTX方案具有更优的表现，满足了患者对更高生活质量的追求。DESTINY-Gastric04研究中T-DXd与RAM+PTX方案的中位治疗时间分别为5.4个月和4.6个月，T-DXd较RAM+PTX≥3级治疗期间不良事件（TEAE）发生率更低，为50.0% vs 54.1%，导致减量和治疗中断的TEAE发生率也更低，耐受性更好。在临床关注的间质性肺病（ILD）方面，T-DXd的≥3级ILD发生率仅0.4%，无致死病例。中国人群耐受性可能更好，另一项DESTINY-Gastric06研究显示中国人群≥3级ILD发生率为0%。该方案为HER2阳性胃癌二线治疗领域首个豁免化疗方案，避免了二线系统化疗带来的安全性风险，在心理层面也让患者更容易接受，是在安全性、耐受性、依从性方面契合中国胃癌患者需求的治疗新选择。在参与DESTINY-Gastric04研究的临床实践中，我们发现T-DXd组患者缩瘤速度快、可维持较长的疾病缓解时间，使患者的整体治疗体验较好，增强了患者的治疗信心，最终延长了患者的生存时间。因此，在临床实践中，对于HER2阳性胃癌患者的二线治疗，建议优选T-DXd。铸就胃癌二线治疗新标准迈向健康中国2030 HER2阳性胃癌是胃癌中重要的分子亚型，抗HER2治疗为此类患者的生存带来了质的飞跃。此次T-DXd在我国获批胃癌二线治疗适应症，无疑填补了我国二线治疗的空白。基于T-DXd机制层面的抗体依赖的细胞介导的细胞毒作用（ADCC）、化疗细胞毒作用以及旁观者效应，其在DESTINY-Gastric04研究的不同亚组中展现了一致的临床获益，对HER2阳性胃癌患者具有普适性。随着其新适应症的获批及可及性的提升，佐以临床实践的便捷性和安全性，T-DXd将有力推动我国胃癌诊疗的均质化、同质化，提升我国整体胃癌的诊疗水平。如今，T-DXd铸就了HER2阳性胃癌二线治疗新标准，改写了HER2阳性胃癌治疗格局。《ESMO泛亚洲临床实践指南：胃癌诊断、治疗和随访(2024)》[14]、《NCCN胃癌临床实践指南 2026v1》[15]均将T-DXd作为HER2晚期胃癌二线及以上治疗的优选高级别推荐方案，塑造了全新的胃癌抗HER2治疗格局。相信在2026年即将迎来的《中国临床肿瘤学会（CSCO）胃癌诊疗指南》更新中，我们将看到T-DXd被纳入其中，并被赋予高级别的推荐等级，成为我国的标准治疗方案。《NCCN胃癌指南2026v1》推荐T-DXd为HER2阳性胃癌二线及以上优选方案（Preferred Category 1）展望未来，我们将持续把握前沿进展、普及最新的二线抗HER2治疗策略，让更多患者在精准治疗中获得生命的延长和生命质量的提升，最终助力实现“健康中国2030”提升癌症患者整体生存率的宏伟目标。参考文献：（滑动查看） 1 Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47-53. Published 2024 Feb 2. doi:10.1016/j.jncc.2024.01.006 2 Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025;18(1):42. Published 2025 Apr 15. doi:10.1186/s13045-025-01698-y 3 Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197-2208. doi:10.1016/S0140-6736(23)02033-0 4 Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X 5 Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-2049. doi:10.1200/JCO.2013.53.6136 6 Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640-653. doi:10.1016/S1470-2045(17)30111-0 7 Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919-1927. doi:10.1200/JCO.19.03077 8 Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6 9 Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413 10 Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. EClinicalMedicine. 2025;87:103404. Published 2025 Aug 11. doi:10.1016/j.eclinm.2025.103404 11 Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173-1182. doi:10.1002/cac2.12214 12 Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744-756. doi:10.1016/S1470-2045(23)00215-2 13 Shitara K, Van Cutsem E, Gümüş M, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336-348. doi:10.1056/NEJMoa2503119 14 Shitara K, Fleitas T, Kawakami H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. 2024;9(2):102226. doi:10.1016/j.esmoop.2023.102226 15 National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology （NCCN Guidelines®）: Gastric Cancer. Version 1. 2026. 2026.02.11. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf 刘天舒教授主任医师、博士生导师复旦大学附属中山医院肿瘤内科主任肿瘤早期研究病房主任复旦大学附属中山医院肿瘤防治中心秘书长上海市肿瘤化疗质量控制中心主任上海市医学会临床流行病学循证医学专科第七/八届主任委员 CSCO抗肿瘤药物安全管理专委会/转化医学专委会副主任委员中国女医师协会临床肿瘤专委会副主任委员 CSCO临床研究专委会/胃癌专委会常委中国抗癌协会第六届胃癌专业委员会常委中国抗癌协会肿瘤大数据与真实世界研究专委会常委中华医学会肿瘤学分会委员中国生物医学工程学会肿瘤靶向治疗技术分会常委中国老年学会肿瘤康复分会常委相关推荐 1 沈琳教授：德曲妥珠单抗获NMPA批准HER2阳性胃癌二线治疗适应症，抗HER2治疗再塑胃癌生存新高度 2 一图读懂丨T-DXd获批HER2阳性胃癌二线治疗适应症的前世今生 3 HER2研究者说胃癌篇丨张小田教授：再树胃癌抗HER2里程碑，德曲妥珠单抗新适应症革新胃癌二线治疗格局（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床结果多肽偶联药物

100 项与帕博利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10574	帕博利珠单抗	L01XC18	DB09037

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肿瘤	美国	Merck Sharp & Dohme LLC	2026-02-10
卵巢癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肌层浸润性膀胱癌	美国	Merck Sharp & Dohme LLC	2025-11-21
局部晚期头颈部鳞状细胞癌	欧盟	Merck Sharp & Dohme BV	2025-10-30
局部晚期头颈部鳞状细胞癌	冰岛	Merck Sharp & Dohme BV	2025-10-30
局部晚期头颈部鳞状细胞癌	列支敦士登	Merck Sharp & Dohme BV	2025-10-30
局部晚期头颈部鳞状细胞癌	挪威	Merck Sharp & Dohme BV	2025-10-30
不可切除的肝细胞癌	中国	Merck Sharp & Dohme LLC	2025-06-10
不可切除的胸膜恶性间皮瘤	欧盟	Merck Sharp & Dohme BV	2025-04-16
不可切除的胸膜恶性间皮瘤	冰岛	Merck Sharp & Dohme BV	2025-04-16
不可切除的胸膜恶性间皮瘤	列支敦士登	Merck Sharp & Dohme BV	2025-04-16
不可切除的胸膜恶性间皮瘤	挪威	Merck Sharp & Dohme BV	2025-04-16
不可切除的尿路上皮癌	欧盟	Merck Sharp & Dohme BV	2024-07-25
不可切除的尿路上皮癌	冰岛	Merck Sharp & Dohme BV	2024-07-25
不可切除的尿路上皮癌	列支敦士登	Merck Sharp & Dohme BV	2024-07-25
不可切除的尿路上皮癌	挪威	Merck Sharp & Dohme BV	2024-07-25
晚期子宫内膜癌	美国	Merck Sharp & Dohme LLC	2024-06-17
MSI-H 子宫内膜癌	美国	Merck Sharp & Dohme LLC	2024-06-17
错配修复缺陷子宫内膜癌	美国	Merck Sharp & Dohme LLC	2024-06-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性铂耐药性卵巢癌	申请上市	美国	Merck & Co., Inc.	2025-10-20
小肠癌	申请上市	欧盟	Merck Sharp & Dohme Corp.	2022-03-25
癫痫发作	临床3期	美国	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	中国	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	日本	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	阿根廷	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	比利时	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	巴西	Merck Sharp & Dohme LLC	2025-07-08
癫痫发作	临床3期	加拿大	Merck Sharp & Dohme LLC	2025-07-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03990961 (CTgov)	临床2期	弥漫性大B细胞淋巴瘤 \| 复发性弥漫性大B细胞淋巴瘤	5	Pembrolizumab	製夢繭範醖窪繭廠繭餘 = 範顧網選顧糧鏇鬱鏇積積醖夢醖範醖醖簾選簾 (壓網襯壓遞網醖簾遞鬱, 鏇餘糧鬱襯廠夢鏇築膚 ~ 淵選鏇醖襯淵獵壓築築) 更多	-	2026-02-20
NCT03123276 (GEMMK, CTgov)	临床1/2期	恶性纤维组织细胞瘤 \| 平滑肌肉瘤	25	Gemcitabine (Cohort 1 - 800mg/m2 Gemcitabine)	築遞繭鏇製鏇艱醖觸構 = 淵繭廠夢遞顧獵糧獵鹹願鹽憲構構醖鬱鏇鑰衊 (憲壓衊製構顧網淵襯積, 簾構獵積艱衊廠鑰築鹽 ~ 觸齋鑰簾鹽構積蓋鑰鹽) 更多	-	2026-02-13
NCT03123276 (GEMMK, CTgov)	临床1/2期	恶性纤维组织细胞瘤 \| 平滑肌肉瘤	25	Gemcitabine (Cohort 2 - 1000mg/m2 of Gemcitabine)	築遞繭鏇製鏇艱醖觸構 = 鑰糧鑰製獵醖鹽衊選膚願鹽憲構構醖鬱鏇鑰衊 (憲壓衊製構顧網淵襯積, 獵遞選繭築膚製觸築願 ~ 淵壓鬱齋鹽繭夢蓋壓餘)	-	2026-02-13
NCT04848337 (PLANE-PC, CTgov)	临床2期	神经内分泌肿瘤 \| 转移性前列腺癌 \| 神经内分泌前列腺癌	45	Pembrolizumab+Lenvatinib	築艱獵願醖糧遞鹹製廠(獵醖顧願顧觸構遞壓鏇) = 繭積蓋窪膚築願衊夢糧襯憲廠鹽鏇築顧壓襯製 (淵艱衊餘淵繭衊遞壓繭, 選淵簾選襯鏇範鬱鹽衊 ~ 繭淵獵網選膚膚網襯壓) 更多	-	2026-02-12
NCT03993353 (CTgov)	临床2期	转移性头颈部鳞状细胞癌 \| 晚期头颈癌 \| 食管癌 ... 更多	7	Pembrolizumab+Tadalafil	鹹壓願餘憲醖衊憲蓋艱 = 廠願餘窪醖壓糧膚襯積獵齋餘壓壓鬱醖製鏇簾 (獵顧獵鑰願製齋鏇選齋, 鬱壓廠糧廠夢鹹築選顧 ~ 糧鏇築鏇憲廠遞鹽製衊) 更多	-	2026-02-12
NCT03559049 (CTgov)	临床1/2期	转移性非小细胞肺癌 \| 非鳞状非小细胞肺癌	25	Carboplatin+Pemetrexed+Rucaparib+Pembrolizumab	鏇繭簾範憲鏇鑰膚觸鹹(壓膚醖齋鹽糧獵願廠齋) = 範簾構鹽願淵顧艱膚淵繭鑰鹽衊遞淵鏇壓鏇積 (蓋簾構網淵鹽鹽廠觸醖, 廠蓋網鏇鏇淵廠廠鏇範 ~ 遞鏇襯艱齋顧鹽獵醖膚) 更多	-	2026-02-12
NCT03237572 (Breast-48, CTgov)	临床1期	转移性乳腺癌	13	High-intensity focused ultrasound (HIFU)+pembrolizumab (Arm A: 1st Dose of Pembrolizumab After HIFU)	膚蓋積鑰簾獵獵糧積襯(鑰壓廠襯鏇範築蓋顧餘) = 壓鹽鏇製鹽積獵顧蓋鏇廠餘艱餘鏇鏇鹽構選顧 (齋鹽簾築觸遞糧簾獵鑰, 64.38) 更多	-	2026-02-09
NCT03237572 (Breast-48, CTgov)	临床1期	转移性乳腺癌	13	High-intensity focused ultrasound (HIFU)+pembrolizumab (Arm B: 1st Dose of Pembrolizumab Before HIFU)	膚蓋積鑰簾獵獵糧積襯(鑰壓廠襯鏇範築蓋顧餘) = 淵廠鑰遞製網衊壓鏇衊廠餘艱餘鏇鏇鹽構選顧 (齋鹽簾築觸遞糧簾獵鑰, 216.16) 更多	-	2026-02-09
NCT04166734 (MESO-PRIME, CTgov)	临床1期	不可切除的胸膜恶性间皮瘤 \| 恶性胸膜间皮瘤	5	Stereotactic Body Radiotherapy (SBRT)+Pembrolizumab (Initial Safety Cohort)	憲築築鹽範夢積蓋醖簾 = 衊夢衊襯選鏇製壓夢蓋鬱齋艱襯選範壓餘鏇鬱 (選壓鬱築築淵壓蓋積顧, 鑰積鹹窪衊構繭壓構遞 ~ 壓膚淵獵糧網築選選憲) 更多	-	2026-02-04
NCT04166734 (MESO-PRIME, CTgov)	临床1期	不可切除的胸膜恶性间皮瘤 \| 恶性胸膜间皮瘤	5	Stereotactic Body Radiotherapy (SBRT)+Pembrolizumab (Expansion Cohort)	範鹽積夢選獵衊衊膚鏇 = 構糧觸願構遞憲鹹網衊齋選淵壓積艱願網觸積 (網齋鹹範築壓鹹鬱衊遞, 憲鑰遞壓遞鹽獵艱壓鹹 ~ 衊鹹蓋鏇窪鹽襯鑰積顧) 更多	-	2026-02-04
NCT03727880 (CTgov)	临床2期	胰腺导管腺癌	28	Pembrolizumab+Defactinib (Arm A - Pembrolizumab and Defactinib)	鹹獵鹽顧築醖夢淵襯鹹 = 顧艱襯壓醖淵獵艱顧膚壓壓艱構構鏇齋廠壓網 (積繭壓蓋艱糧艱鬱餘鬱, 願鬱鹹積積襯鬱蓋鹽壓 ~ 選鏇築範襯範餘製壓廠) 更多	-	2026-02-04
NCT03727880 (CTgov)	临床2期	胰腺导管腺癌	28	Pembrolizumab (Arm B - Pembrolizumab)	鹹獵鹽顧築醖夢淵襯鹹 = 夢積齋餘觸構膚齋鑰餘壓壓艱構構鏇齋廠壓網 (積繭壓蓋艱糧艱鬱餘鬱, 壓壓壓壓築淵製蓋獵簾 ~ 糧網窪蓋夢廠範觸蓋鑰) 更多	-	2026-02-04
NCT04699071 (LARA, Pubmed \| Lancet Oncol)	临床2期	透明细胞腺癌	27	PembrolizumabLenvatinibmab + PembrolizumabLenvatinib (Recurrent gynaecological clear cell carcinoma)	鏇觸醖餘網製選淵鬱膚(襯窪淵鑰蓋網鬱衊窪壓) = 觸蓋願窪鹽鏇獵築觸齋鏇廠鏇襯艱蓋築淵糧醖 (艱遞製糧艱網壓顧壓繭, 21 ~ 61) 更多	积极	2026-02-01
NCT02422381 (CTgov)	临床1/2期	非小细胞肺癌	16	Gemcitabine+MK-3475	網鏇夢願範觸遞鹹廠鑰 = 築鹹範築築願遞製鹽願網襯壓鹹憲鑰簾鹹廠襯 (窪淵窪膚壓夢顧遞選顧, 蓋積鹹築淵製夢衊積鬱 ~ 獵築膚衊積顧網齋選積) 更多	-	2026-01-29